Cargando…

Postoperative adjuvant TACE for patients of hepatocellular carcinoma in AJCC stage I: friend or foe? a propensity score analysis

BACKGROUND: Although the transcatheter arterial chemoembolization (TACE) was demonstrated to be an alternative treatment of hepatocellular carcinoma with favorable oncological effect, the benefit of postoperative adjuvant TACE was still controversial. The aim of this study was to evaluate the effect...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tong, Yifan, Li, Zheyong, Liang, Yuelong, Yu, Hong, Liang, Xiao, Liu, Hui, Cai, Xiujun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5432288/ https://www.ncbi.nlm.nih.gov/pubmed/28460456 http://dx.doi.org/10.18632/oncotarget.15793

Ejemplares similares

Transarterial Chemoembolization (TACE) Combined with Sorafenib versus TACE Alone for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Study
por: Ren, Baosheng, et al.
Publicado: (2019)

Estrogens in Hepatocellular Carcinoma: Friends or Foes?
por: Carruba, Giuseppe
Publicado: (2021)

Comparing the effectiveness and safety of Sorafenib plus TACE with Apatinib plus TACE for treating patients with unresectable hepatocellular carcinoma: a multicentre propensity score matching study
por: Yin, Liang, et al.
Publicado: (2023)

Prognostic Comparison between cTACE and H101-TACE in Unresectable Hepatocellular Carcinoma (HCC): A Propensity-Score Matching Analysis
por: Yao, Man, et al.
Publicado: (2022)

Cezanne predicts progression and adjuvant TACE response in hepatocellular carcinoma
por: Wang, Jia-hong, et al.
Publicado: (2017)

The role of autophagy in hepatocellular carcinoma: friend or foe
por: Liu, Lian, et al.
Publicado: (2017)

ZEB Proteins in Leukemia: Friends, Foes, or Friendly Foes?
por: Soen, Bieke, et al.
Publicado: (2018)

Friend and Foe
Publicado: (1890)

Development of TACE Refractoriness Scores in Hepatocellular Carcinoma
por: Chen, Li, et al.
Publicado: (2021)

Efficacy of adjuvant TACE on the prognosis of patients with HCC after hepatectomy: a multicenter propensity score matching from China
por: Wu, Zhao, et al.
Publicado: (2023)

TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus: a propensity score matching study
por: Yuan, Yichuan, et al.
Publicado: (2023)

Tumor-Associated Macrophages in Hepatocellular Carcinoma: Friend or Foe?
por: Zhou, Dexi, et al.
Publicado: (2021)

RMP predicts survival and adjuvant TACE response in hepatocellular carcinoma
por: Zhang, Jian, et al.
Publicado: (2014)

Transcriptome Analysis of Solute Carrier-Associated Genes in Hepatocellular Carcinoma: Friend or Foe?
por: Wei, Wei, et al.
Publicado: (2022)

Nomogram for individualized prediction of recurrence after postoperative adjuvant TACE for hepatitis B virus-related hepatocellular carcinoma
por: Jiang, Jiang, et al.
Publicado: (2017)

Fibroblasts in cancer dormancy: foe or friend?
por: Dai, Li, et al.
Publicado: (2021)

Efficacy Of Apatinib In Transcatheter Arterial Chemoembolization (TACE) Refractory Intermediate And Advanced-Stage Hepatocellular carcinoma：A Propensity Score Matching Analysis
por: Qiu, Zhiyu, et al.
Publicado: (2019)

Phytoestrogens. Friends or foes?
por: Barrett, J
Publicado: (1996)

Polypill—Friend or Foe?
por: Rishi, Rakesh Kumar
Publicado: (2011)

Antioxidants - friend or foe?
por: Meffert, Hans
Publicado: (2008)

Inflammation: Friend and Foe
por: Kjekshus, John
Publicado: (2015)

Leukocytes: friend or foe
por: Bellingan, G
Publicado: (2000)

Viruses: Friends or foes
por: Michán, Carmen, et al.
Publicado: (2021)

Sphingolipids: Friends or Foes?
por: Hayashi, Hiroshi
Publicado: (2022)

Gabapentin—Friend or foe?
por: Russo, Marc, et al.
Publicado: (2022)

Duration of response after DEB-TACE compared to lipiodol-TACE in HCC-naïve patients: a propensity score matching analysis
por: Bargellini, Irene, et al.
Publicado: (2021)

IL-33 in COVID-19: friend or foe?
por: Liang, Yuejin, et al.
Publicado: (2021)

Natural killer cells in sepsis: Friends or foes?
por: Wang, Fangjie, et al.
Publicado: (2023)

Serum alanine aminotransferase to hemoglobin ratio and radiological features predict the prognosis of postoperative adjuvant TACE in patients with hepatocellular carcinoma
por: Xia, Zicong, et al.
Publicado: (2022)

Single medium-sized hepatocellular carcinoma treated with sequential conventional transarterial chemoembolization (cTACE) and microwave ablation at 4 weeks versus cTACE alone: a propensity score
por: Zhu, Zi-yi, et al.
Publicado: (2022)

Tim-4 in Health and Disease: Friend or Foe?
por: Liu, Wen, et al.
Publicado: (2020)

Clinical outcomes of hepatocellular carcinoma patients after hepatectomy treated with TACE in combination with sorafenib: a propensity score matched analysis
por: Li, Yujie, et al.
Publicado: (2023)

Friend or Foe? Locoregional Therapies and Immunotherapies in the Current Hepatocellular Treatment Landscape
por: Young, Shamar, et al.
Publicado: (2023)

Media and breastfeeding: Friend or foe?
por: Brown, Jane D, et al.
Publicado: (2008)

Friend to the brain, foe to the spine
por: Maxmen, Amy
Publicado: (2008)

Podiatric surgery: friend or foe?
por: Prior, Trevor D
Publicado: (2011)

Medicine And Money: Friends Or Foe?
por: Muula, Adamson S.
Publicado: (2006)

Bacterial toxins: friends or foes?
por: Schmitt, C K, et al.
Publicado: (1999)

HAART and the liver: friend or foe?
por: Pineda, JA, et al.
Publicado: (2010)

Cricoid pressure – friend or foe?
por: Harris, Tim, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_aihnnj83lmitdh6hcl1351vel0